Physician profile
Hailey Dunn
NPI 1083249213
$6,146.65
in general payments reported to CMS, 2019-2025
49 companies · $2,040 in 2025
The $2,040 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,408 · 2022: $625 · 2023: $847 · 2024: $1,227 · 2025: $2,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,013 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,012.68 |
| Education | $100.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,183.12 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $565.27 | 2021-2025 | |
| Pfizer INC. | $483.00 | 2023-2025 | |
| Biogen, INC. | $299.90 | 2021-2025 | Tysabri, Spinraza, Qalsody |
| Lundbeck LLC | $247.68 | 2021-2025 | Vyepti, Rexulti |
| Ucb, INC. | $246.23 | 2021-2025 | Nayzilam, Briviact, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $238.21 | 2021-2025 | Austedo Xr, Austedo |
| Emd Serono, INC. | $228.74 | 2021-2025 | Mavenclad |
| Acadia Pharmaceuticals INC | $219.16 | 2021-2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $159.42 | 2021 | |
| Ani Pharmaceuticals, INC. | $134.70 | 2024-2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $125.65 | 2023-2025 | Rexulti, Nuedexta |
| Sk Life Science, INC. | $121.74 | 2021-2025 | |
| Boston Scientific Corporation | $102.72 | 2024-2025 | General - Dbs |
| Neurocrine Biosciences, INC. | $95.28 | 2021-2025 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $93.70 | 2021-2022 | |
| Neurelis, INC. | $92.39 | 2021-2025 | Valtoco |
| Eisai INC. | $90.17 | 2022-2025 | |
| Argenx US, INC. | $84.50 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Sunovion Pharmaceuticals INC. | $84.17 | 2021-2022 | |
| Tg Therapeutics, INC. | $84.11 | 2025 | |
| Genentech USA, INC. | $82.21 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Abbott Laboratories | $80.40 | 2024-2025 | Infinity |
| Banner Life Sciences, LLC | $77.02 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $74.58 | 2021-2025 | Acthar |
| Amgen INC. | $72.43 | 2021-2024 | Uplizna |
| Allergan, INC. | $66.84 | 2021-2022 | |
| Averitas Pharma INC. | $63.72 | 2024-2025 | Qutenza |
| Sumitomo Pharma America, INC. | $60.52 | 2023 | Aptiom |
| Lilly USA, LLC | $55.82 | 2021-2025 | Kisunla, Emgality, Reyvow |
| Tanabe Pharma America, INC. | $52.33 | 2021-2025 | Radicava |
| Kyowa Kirin, INC. | $49.33 | 2021-2024 | Nourianz |
| Medtronic, INC. | $48.08 | 2022-2025 | Percept PC Brainsense |
| Janssen Pharmaceuticals, INC | $44.88 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $40.39 | 2024-2025 | |
| Mdd US Operations, LLC | $38.14 | 2022-2024 | Gocovri |
| Upsher-Smith Laboratories LLC | $32.65 | 2021-2022 | |
| Almatica Pharma LLC | $31.57 | 2021 | |
| Alexion Pharmaceuticals, INC. | $25.48 | 2024 | Ultomiris |
| Biodelivery Sciences International, INC. | $24.73 | 2021 | |
| Corium, LLC | $23.47 | 2023 | Adlarity |
| Chiesi USA, INC. | $19.88 | 2023 | Cleviprex |
| Acorda Therapeutics, INC | $19.31 | 2021 | |
| Grifols USA, LLC | $18.58 | 2025 | Gamunex-C |
| Avanir Pharmaceuticals, INC. | $15.42 | 2022 | |
| Horizon Therapeutics Plc | $13.02 | 2021 | |
| Adamas Pharmaceuticals, INC. | $12.71 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.21 | 2021 | |
| Collegium Pharmaceutical, INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.